AMGN241129C332500
- 0.53
- +0.18+51.43%
Amgen Newsroom
S&P 500, Dow Hit Records Right After Open | Live Stock
Express News | Amgen Inc : RBC Cuts Target Price to $360 From $362
Is There An Opportunity With Amgen Inc.'s (NASDAQ:AMGN) 49% Undervaluation?
Trump Nominates Marty Makary For FDA Commissioner
The Trader: Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop -- Barron's
Trump Picks Surgeon Makary to Head FDA, Rep. Dave Weldon to Lead CDC
Weekly Buzz: Nvidia Falls on Near Perfect Report, but Only For a Day
Market Climbs, Bitcoin Close to $100k | Live Stock
Viking Therapeutics a New Buy at B Riley on Lead Obesity Asset VK2735
Astrazeneca (AZN.US) and Amgen (AMGN.US) have reported the launch of a subcutaneous injection of TSLP monoclonal antibody in China.
CDE's official website shows that Astrazeneca (AZN.US) and Amgen (AMGN.US) have jointly submitted the application for the listing of TSLP monoclonal antibody Tezepelumab injection.
BMO Capital Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $362
Amgen (AMGN.US) weight loss drug is poised to launch, and Wall Street is eagerly awaiting the research results.
Amgen (AMGN.US) will soon release mid-term study data for the experimental weight loss drug MariTide, revealing a comparison of this drug with GLP-1 drugs from Eli Lilly (LLY.US) and novo-nordisk A/S (NVO.US).
Bitcoin Hits $99k, Thursday Market Whiplash Following Nvidia Price | Wall Street Today
Optimism Over Global Healthcare Sector Rises: Jefferies
Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs
Bitcoin Hits $98k, Nvidia Falls on Forward Guidance, Google Chrome Break-Up | Live Stock
Jefferies Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
Jefferies Sticks to Their Buy Rating for Amgen (AMGN)
Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop -- Barrons.com
Nvidia Forward Guidance Was Not Perfect, Market Flat | Wall Street Today